{"id":"prednisone-taper","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes (anxiety, irritability)"},{"rate":null,"effect":"Increased infection risk"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Adrenal suppression"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":null,"_dailymed":{"setId":"2de07baf-1add-f3d1-e063-6394a90a41d8","title":"P- PACK PREDNISONE 20MG, 7- DAY TAPERING DOSE PACK (DR ADAM AU) TABLET [INTERSTELLAR PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisone enters cells and binds to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and proliferation. A taper refers to a gradual dose reduction to allow the hypothalamic-pituitary-adrenal (HPA) axis to recover normal function.","oneSentence":"Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:05:53.320Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune conditions (rheumatoid arthritis, lupus, vasculitis)"},{"name":"Allergic reactions and asthma exacerbations"},{"name":"Adrenal insufficiency"},{"name":"Certain malignancies (lymphomas, leukemias)"},{"name":"Organ transplant rejection prophylaxis"}]},"trialDetails":[{"nctId":"NCT05789030","phase":"NA","title":"Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-01","conditions":"Autoimmune Diseases","enrollment":60},{"nctId":"NCT05123040","phase":"PHASE1, PHASE2","title":"Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2023-06-05","conditions":"Acute-graft-versus-host Disease","enrollment":10},{"nctId":"NCT05917522","phase":"PHASE2","title":"Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Kidney Transplant","enrollment":800},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT03663933","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-04","conditions":"Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders","enrollment":71},{"nctId":"NCT06533098","phase":"PHASE3","title":"A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-02-10","conditions":"Thrombocytopenia, Neonatal Alloimmune","enrollment":50},{"nctId":"NCT05379634","phase":"PHASE2","title":"A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-05","conditions":"Myositis","enrollment":36},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT06918990","phase":"PHASE2","title":"Treatment of Antibody-Mediated Rejection (ABMR) With CarBel","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-15","conditions":"Kidney Transplant Rejection","enrollment":25},{"nctId":"NCT07453368","phase":"PHASE2","title":"Orelabrutinib in the Treatment of Relapsed/Refractory AIHA","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-03-01","conditions":"Autoimmune Hemolytic Anemia (AIHA)","enrollment":50},{"nctId":"NCT05767034","phase":"PHASE3","title":"Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-03-22","conditions":"Polymyalgia Rheumatica","enrollment":381},{"nctId":"NCT06563323","phase":"PHASE2","title":"Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)","status":"RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2025-02-01","conditions":"Pyoderma Gangrenosum, Skin Diseases, Wound Heal","enrollment":17},{"nctId":"NCT05039619","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-05-12","conditions":"Lupus Nephritis","enrollment":40},{"nctId":"NCT07451665","phase":"PHASE4","title":"Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis","status":"NOT_YET_RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2026-04-01","conditions":"Takayasu Arteritis (TAK)","enrollment":180},{"nctId":"NCT07245732","phase":"PHASE4","title":"Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares","status":"NOT_YET_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2026-04","conditions":"Rheumatoid Arthritis (RA)","enrollment":220},{"nctId":"NCT03187743","phase":"NA","title":"Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-04-17","conditions":"Lupus Erythematosus, Systemic","enrollment":72},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07221838","phase":"PHASE4","title":"A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab","status":"NOT_YET_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2026-02-27","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":75},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT07087314","phase":"PHASE2","title":"A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence","status":"RECRUITING","sponsor":"Mao Jianhua","startDate":"2025-08-25","conditions":"Nephrotic Syndrome in Children","enrollment":30},{"nctId":"NCT04438382","phase":"PHASE2","title":"Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-01-07","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis","enrollment":1},{"nctId":"NCT04930094","phase":"PHASE3","title":"Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-06","conditions":"Giant Cell Arteritis (GCA)","enrollment":355},{"nctId":"NCT03153527","phase":"PHASE4","title":"Taper Or Abrupt Steroid Stop: TOASSTtrial","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-05-31","conditions":"Inflammatory Disorder, Autoimmune","enrollment":530},{"nctId":"NCT05470491","phase":"PHASE1, PHASE2","title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-01-26","conditions":"HIV, Hematologic Malignancies","enrollment":265},{"nctId":"NCT03725202","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-01-24","conditions":"Giant Cell Arteritis (GCA)","enrollment":429},{"nctId":"NCT07420296","phase":"PHASE4","title":"Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-01-01","conditions":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":198},{"nctId":"NCT07418177","phase":"PHASE1, PHASE2","title":"Study in Human iPSCs-derived RPE Cells Transplantation for Late-Stage AMD","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-10","conditions":"AMD - Age-Related Macular Degeneration","enrollment":9},{"nctId":"NCT07406932","phase":"NA","title":"A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","startDate":"2026-02-01","conditions":"Antisynthetase Syndrome, Interstitial Lung Disease (ILD)","enrollment":80},{"nctId":"NCT04408625","phase":"PHASE1, PHASE2","title":"Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2020-11-09","conditions":"Frontotemporal Dementia","enrollment":35},{"nctId":"NCT07286214","phase":"PHASE4","title":"Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-04-15","conditions":"Polymyalgia Rheumatica","enrollment":300},{"nctId":"NCT06868381","phase":"PHASE2","title":"A Trial of Baricitinib in Patients With Cardiac Sarcoidosis","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-04-01","conditions":"Cardiac Sarcoidosis","enrollment":10},{"nctId":"NCT04221477","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Lupus Nephritis","enrollment":271},{"nctId":"NCT04918147","phase":"PHASE2","title":"Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":"IgG4 Related Disease, IgG4-RD","enrollment":8},{"nctId":"NCT07258771","phase":"PHASE4","title":"Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2026-01-16","conditions":"Ulcerative Colitis Acute","enrollment":110},{"nctId":"NCT06983821","phase":"PHASE3","title":"Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2025-11-10","conditions":"Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA)","enrollment":36},{"nctId":"NCT04305145","phase":"PHASE2","title":"Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-08-31","conditions":"Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III","enrollment":42},{"nctId":"NCT06342544","phase":"PHASE3","title":"Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.","status":"RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2025-04-29","conditions":"Ocular Myasthenia Gravis","enrollment":128},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT04151082","phase":"PHASE1, PHASE2","title":"High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-16","conditions":"Cranial Nerve Disorder, Head and Neck Carcinoma, Oropharyngeal Carcinoma","enrollment":35},{"nctId":"NCT06452537","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Tocilizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2024-07-09","conditions":"Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease","enrollment":102},{"nctId":"NCT06001125","phase":"PHASE2","title":"Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1)","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2024-08-12","conditions":"Arthritis, Arthralgia","enrollment":27},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT05201469","phase":"PHASE2","title":"VIBRANT: VIB4920 for Active Lupus Nephritis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-05-16","conditions":"Lupus Nephritis","enrollment":74},{"nctId":"NCT03009981","phase":"PHASE3","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-03-06","conditions":"Prostate Cancer","enrollment":504},{"nctId":"NCT04104438","phase":"PHASE4","title":"Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant","status":"COMPLETED","sponsor":"Fady M Kaldas, M.D., F.A.C.S.","startDate":"2021-01-15","conditions":"Asses Immunosuppression Modulation on Renal Recovery Post LT","enrollment":71},{"nctId":"NCT04411654","phase":"PHASE1, PHASE2","title":"Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prevail Therapeutics","startDate":"2021-06-29","conditions":"Gaucher Disease, Type 2","enrollment":7},{"nctId":"NCT05627557","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-03-29","conditions":"Childhood Idiopathic Nephrotic Syndrome","enrollment":85},{"nctId":"NCT04745728","phase":"PHASE3","title":"Different Immunosuppressive Treatment in iMN","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":200},{"nctId":"NCT04540380","phase":"PHASE1","title":"Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-09-01","conditions":"Renal Failure","enrollment":20},{"nctId":"NCT02997605","phase":"PHASE4","title":"Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-01-31","conditions":"RheumatoId Arthritis","enrollment":102},{"nctId":"NCT03892785","phase":"PHASE3","title":"MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-01-27","conditions":"Giant Cell Arteritis","enrollment":230},{"nctId":"NCT00748644","phase":"PHASE3","title":"Efficacy Study of Two Treatments in the Remission of Vasculitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-10","conditions":"Wegener Granulomatosis, Microscopic Polyangiitis","enrollment":117},{"nctId":"NCT06072768","phase":"PHASE2","title":"Dynamic Treatment Regiments for Glucocorticoid Tapering","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2023-03-09","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT04833907","phase":"PHASE1, PHASE2","title":"rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Myrtelle Inc.","startDate":"2021-04-01","conditions":"Canavan Disease","enrollment":24},{"nctId":"NCT06453694","phase":"PHASE2","title":"Efgartigimod for the Treatment of Acute Optic Neuritis","status":"RECRUITING","sponsor":"Anastasia Vishnevetsky, MD, MPH","startDate":"2025-08-12","conditions":"Optic Neuritis","enrollment":20},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT06841705","phase":"PHASE2","title":"Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial","status":"RECRUITING","sponsor":"Shilpa Grover, MD, MPH","startDate":"2025-07-15","conditions":"Immune Checkpoint Inhibitor-Related Colitis","enrollment":80},{"nctId":"NCT03595917","phase":"PHASE1","title":"ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML","status":"RECRUITING","sponsor":"Marlise Luskin, MD","startDate":"2018-07-24","conditions":"B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL","enrollment":40},{"nctId":"NCT04520451","phase":"PHASE2","title":"Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants","status":"COMPLETED","sponsor":"Principia Biopharma, a Sanofi Company","startDate":"2020-08-22","conditions":"Immunoglobulin G4 Related Disease","enrollment":27},{"nctId":"NCT06676579","phase":"PHASE2","title":"Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-06-09","conditions":"IgA Nephropathy (IgAN)","enrollment":16},{"nctId":"NCT07049172","phase":"NA","title":"Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome","status":"COMPLETED","sponsor":"Wuhan Children's Hospital","startDate":"2021-01-01","conditions":"Nephrotic Syndrome in Children","enrollment":91},{"nctId":"NCT02356159","phase":"PHASE1, PHASE2","title":"Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-24","conditions":"Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":34},{"nctId":"NCT06478017","phase":"PHASE2","title":"Belatacept in Heart Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-01-29","conditions":"Heart Transplant","enrollment":66},{"nctId":"NCT04875702","phase":"PHASE4","title":"Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-02-22","conditions":"Gout","enrollment":650},{"nctId":"NCT06598332","phase":"EARLY_PHASE1","title":"5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","startDate":"2025-08","conditions":"Graft-Versus-Host Disease(GVHD)","enrollment":""},{"nctId":"NCT03290456","phase":"NA","title":"Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2019-08-20","conditions":"Granulomatosis With Polyangitis","enrollment":146},{"nctId":"NCT07159893","phase":"NA","title":"Inectolizumab With Steroid Optimization in Newly Treated NMOSD","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-09","conditions":"Neuromyelitis Optica, Autoimmune Diseases, Demyelinating Autoimmune Diseases, CNS","enrollment":25},{"nctId":"NCT01731561","phase":"PHASE3","title":"Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-11-16","conditions":"Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Renal Limited Forms","enrollment":166},{"nctId":"NCT07132398","phase":"PHASE3","title":"Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-01","conditions":"Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":170},{"nctId":"NCT06172361","phase":"PHASE3","title":"Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2024-01-20","conditions":"Polymyalgia Rheumatica","enrollment":98},{"nctId":"NCT04972760","phase":"PHASE3","title":"Baricitinib in Patients With Relapsing or naïve Dermatomyositis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-08-31","conditions":"Dermatomyositis","enrollment":62},{"nctId":"NCT05990894","phase":"","title":"Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-07-01","conditions":"Cerebral Venous Thrombosis","enrollment":170},{"nctId":"NCT02494882","phase":"PHASE1","title":"Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-06-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":12},{"nctId":"NCT03649061","phase":"PHASE4","title":"COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA","status":"COMPLETED","sponsor":"P. Verschueren","startDate":"2018-06-08","conditions":"Arthritis, Rheumatoid","enrollment":276},{"nctId":"NCT04354649","phase":"PHASE2","title":"Immune-Mediated Pathophysiology And Clinical Triage Program","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2021-09-16","conditions":"Arthritis, Arthralgia","enrollment":46},{"nctId":"NCT06280950","phase":"PHASE2","title":"Expanding Liver Transplant Immunosuppression Minimization Via Everolimus","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-12","conditions":"Liver Transplant","enrollment":340},{"nctId":"NCT04901325","phase":"PHASE2","title":"Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2023-10-03","conditions":"Pyoderma Gangrenosum, Skin Diseases, Wound Heal","enrollment":5},{"nctId":"NCT00004448","phase":"PHASE2","title":"Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1997-11","conditions":"IgA Glomerulonephritis","enrollment":96},{"nctId":"NCT05090384","phase":"PHASE2","title":"Pediatric GVHD Low Risk Steroid Taper Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"John Levine","startDate":"2022-10-20","conditions":"Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects","enrollment":50},{"nctId":"NCT02981979","phase":"NA","title":"Takayasu Arteritis Clinical Trial in China","status":"COMPLETED","sponsor":"Jiang lindi","startDate":"2016-12-22","conditions":"Takayasu Arteritis","enrollment":116},{"nctId":"NCT04339062","phase":"PHASE1, PHASE2","title":"Cemiplimab in AlloSCT/SOT Recipients With CSCC","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-11-03","conditions":"Cutaneous Squamous Cell Carcinoma, Advanced Cancer","enrollment":12},{"nctId":"NCT03811366","phase":"NA","title":"Multimodal Analysis and Electroretinogram in VKH From Acute Onset - Part I","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2011-06-01","conditions":"Uveomeningoencephalitic Syndrome, Inflammation, Choroid Disease","enrollment":12},{"nctId":"NCT01940094","phase":"PHASE3","title":"The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-02","conditions":"Granulomatosis With Polyangiitis","enrollment":159},{"nctId":"NCT02496585","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2015-07-08","conditions":"Lung Cancer, Lung Metastases","enrollment":34},{"nctId":"NCT05867329","phase":"PHASE4","title":"Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2023-09-30","conditions":"Ulcerative Colitis Acute","enrollment":162},{"nctId":"NCT06887517","phase":"","title":"Chinese Rheumatism Biobank(CRB)","status":"RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2025-02-10","conditions":"Lupus Erythematosus, Systemic","enrollment":300},{"nctId":"NCT05479448","phase":"","title":"Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-06-03","conditions":"Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA)","enrollment":30},{"nctId":"NCT03585556","phase":"PHASE1","title":"AAVCAGsCD59 for the Treatment of Wet AMD","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-09-13","conditions":"Wet Age-related Macular Degeneration","enrollment":25},{"nctId":"NCT04988256","phase":"EARLY_PHASE1","title":"Cyclosporine Vs Steroids in DRESS","status":"ENROLLING_BY_INVITATION","sponsor":"University of Southern California","startDate":"2021-09-27","conditions":"DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome","enrollment":50},{"nctId":"NCT04314193","phase":"PHASE4","title":"Effectiveness of Methotrexate Versus Prednisone as First-line Therapy for Pulmonary Sarcoidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2020-06-01","conditions":"Sarcoidosis, Pulmonary","enrollment":138},{"nctId":"NCT02994927","phase":"PHASE3","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-15","conditions":"ANCA-Associated Vasculitis","enrollment":331},{"nctId":"NCT05101928","phase":"PHASE4","title":"Ozurdex Monotherapy Trial","status":"WITHDRAWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-11-30","conditions":"Uveitis, Posterior, Uveitis, Intermediate, Panuveitis","enrollment":""},{"nctId":"NCT05591144","phase":"NA","title":"Short-term Oral Prednisone for Acute Subjective Tinnitus","status":"COMPLETED","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2022-10-30","conditions":"Tinnitus, Subjective","enrollment":146},{"nctId":"NCT06833411","phase":"PHASE3","title":"Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone","status":"NOT_YET_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2026-01","conditions":"Giant Cell Arteritis (GCA)","enrollment":178},{"nctId":"NCT06838559","phase":"PHASE4","title":"Clinical Trial on 7-day Followed by Maintenance Therapy for 10 Weeks vs. 14-day and no Maintenance Course of Prednisolone for the Treatment of Infantile Epileptic Spasms Syndrome (IESS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colombo","startDate":"2025-01-01","conditions":"Spasms, Infantile, Prednisolone","enrollment":182},{"nctId":"NCT03312907","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-01","conditions":"Systemic Lupus Erythematosus","enrollment":292},{"nctId":"NCT05349006","phase":"PHASE3","title":"Azathioprine in MOGAD","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2023-12-12","conditions":"Central Nervous System Inflammation, MOG-IgG Associated Disease","enrollment":126},{"nctId":"NCT04046549","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-10-30","conditions":"Allografts, Rejection; Transplant, Kidney, Transplant Rejection","enrollment":25},{"nctId":"NCT06723548","phase":"PHASE4","title":"Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2024-12","conditions":"Myasthenia Gravis, Autoimmune Diseases","enrollment":30},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67}],"_emaApprovals":[],"_faersSignals":[{"count":11,"reaction":"DYSPNOEA"},{"count":7,"reaction":"PNEUMONIA"},{"count":5,"reaction":"CONDITION AGGRAVATED"},{"count":5,"reaction":"PAIN"},{"count":4,"reaction":"DIARRHOEA"},{"count":4,"reaction":"NAUSEA"},{"count":4,"reaction":"PYREXIA"},{"count":4,"reaction":"RASH"},{"count":4,"reaction":"SINUSITIS"},{"count":4,"reaction":"UPPER RESPIRATORY TRACT INFECTION"}],"_approvalHistory":[],"publicationCount":276,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Prednisone Taper","genericName":"Prednisone Taper","companyName":"Shilpa Grover, MD, MPH","companyId":"shilpa-grover-md-mph","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune conditions (rheumatoid arthritis, lupus, vasculitis), Allergic reactions and asthma exacerbations, Adrenal insufficiency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}